Dennis tamed the protein from hell in seven years

February 17, 2021

After seven years of intense research, a research group from Aarhus University has succeeded - through an interdisciplinary collaboration - in understanding why a very extended structure is important for an essential protein from the human immune system. The new results offer new opportunities for adjusting the activity of the immune system both up and down. Stimulation is interesting in relation to cancer treatment, while inhibition of the immune system is used in treatment of autoimmune diseases.

In our bloodstream and tissues, the complement system acts as one of the very first defense mechanisms against pathogenic organisms. When these are detected by the complement system, a chain reaction starts, which ends with the pathogen being eliminated and other parts of the immune system being stimulated. The protein properdin is crucial for the efficiency of the complement system. Fortunately, we almost all have sufficient properdin, as otherwise, we are at risk of dying as a child from infectious diseases.

In 2013, Professor Gregers Rom Andersen from the Department of Molecular Biology and Genetics at Aarhus University was frustrated to know many details about other proteins in the complement system, but properdin seemed to be too difficult to work with. It was known that the protein had a very extended structure, which would make it almost impossible to determine the three-dimensional structure of properdin. To make matters worse, properdin is present in three different forms within the body, so-called oligomers, which contain two, three or four copies of the protein.

"But fortunately, Dennis Vestergaard Pedersen walked in the door in the autumn of 2013 to start as a PhD student. Actually, he only had to work with properdin as a side project as it was too risky. But, one day we sketched on the back of an envelope how one might be able to cut properdin into smaller pieces. It worked surprisingly well," says Gregers Rom Andersen.

In this way, Dennis determined the crystal structure of the individual pieces of a properdin molecule after five years. By then, Dennis had long since finished his PhD and did contract research at Aarhus University. But one thing bothered Dennis.

"Despite five years of work, I still did not know what the properdin oligomers we have in our body look like and what role their unusual and extended structure plays for the function of properdin," says Dennis Vestergaard Pedersen.

"I started for fun studying one of the three properdin oligomers using electron microscopy. To my great surprise, I discovered that this properdin oligomer is a rigid molecule, and not flexible as I had expected. This was a big surprise, and really whet my appetite," Dennis continues.

"In collaboration with colleagues at the University of Copenhagen, I therefore started to study the various properdin oligomers in detail. We combined electron microscopy and a technique called small angle scattering, and we were thus able to prove that all the different properdin oligomers are rigid, spatially well-defined molecules."

The special extended structure of properdin is important for the function of the protein in the immune system

At the same time, Dennis - along with Master thesis student Sofia MM Mazarakis - conducted laboratory experiments comparing the ability of artificial and naturally occurring properdin oligomers to drive the activation of the complement system. By combining these data with structural data, the researchers were able to show that the special extended structure of properdin actually is important for the function of the protein in the immune system.

Gregers Rom Andersen elaborates: "Dennis' long and persistent work with properdin has given us a whole new understanding of "the molecule from hell" and especially why it looks the way it does. It has given us new opportunities in terms of being able to control the activity of the complement system both up and down. Stimulation is interesting in connection with cancer, while shutdown of the complement is already used to treat autoimmune diseases."

Through his long work with properdin, Dennis has for a long time collaborated with a large pharmaceutical company and will now try to develop medicine himself. Together with three other researchers from Aarhus University, Dennis has developed a technique that takes advantage of our body's own complement system to kill cancer cells. The technique has just been patented by Aarhus University, and the researchers are now further developing the technique with support from the Innovation Fund Denmark and the Novo Nordisk Foundation.
-end-
The researchers' work with properdin was supported financially by the Novo Nordisk Foundation and the Lundbeck Foundation.

The research results have just been published in the prestigious scientific journal eLife:

"Properdin oligomers adopt rigid extended conformations supporting function"

Dennis V Pedersen, Martin Nors Pedersen, Sofia MM Mazarakis, Yong Wang, Kresten Lindorff-Larsen, Lise Arleth, Gregers R Andersen

https://elifesciences.org/articles/63356

DOI: 10.7554/eLife.63356

Aarhus University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.